Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.” ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
Scientists from UC Davis Center for Surgical Bioengineering, the MIND Institute and UC Berkeley’s Murthy Lab are developing ...
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
Quest to beat the US saw a Chinese team turn to ancient traditions, leading to a new technique 10 times more effective than ...
Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ), scooping up 145,153 shares in the gene-editing play.
As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback